This evolutionary double bind25,26 has been observed prospectively in colorectal cancer patients under EGFR inhibition, where KRAS-driven resistance seems to imply a cost, and KRAS subclones decrease in relative frequency if the drug is suspended28. This evidence concerns the gene KRAS and colorectal cancer.